#289 Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on the rat bladder with partial bladder outlet obstruction

Presenter: Seiji Matsumoto

#290 Inhibitory effects of Tadalafil on prostate cell growth; a study using a novel human benign prostatic hyperplasia xenografts in super-SCID mice

Presenter: Hiroshi Kiuchi

#291 An inflammatory cytokine IL-1ß is involved in bladder remodelling after partial bladder outlet obstruction in mice

Presenter: Yukiko Kanno

#292 Expression of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) receptor and effects of CB1/CB2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats

Presenter: Kang Jun Cho

#293 Dose escalation of a muscarinic antagonist with THVD-201, a novel combination drug product containing tolterodine and pilocarpine (a muscarinic agonist and salivary stimulant)

Presenter: David Staskin

#294 Post hoc responder analyses of subjective and objective outcomes using pooled data from 3 randomised Phase III trials of mirabegron in patients with overactive bladder

Presenter: David Castro Díaz

#295 Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy and safety results from a randomised phase II study (Symphony)

Presenter: David Staskin

#296 A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO). (EudraCT number: 2011-000250-28)

Presenter: Brigitte Bosman